Terns Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Terns Pharmaceuticals generated cash of -$67,390,000, which is less than the previous year. Cash used in financing activities reached the amount of $41,951,000 last year. Net change in cash is therefore -$63,309,000.
Cash Flow
| 2018 | -18.07M | -4.77M | 99.76M |
|---|---|---|---|
| 2019 | -66.22M | -3.85M | 62K |
| 2020 | -29.80M | 6.69M | 85.51M |
| 2021 | -41.82M | -119.69M | 134.39M |
| 2022 | -49.10M | -22.27M | 167.49M |
| 2023 | -67.39M | -37.98M | 41.95M |
TERN Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 143.23M | 47.69M | 74.85M | 12.37M | 82.52M | 5.50M |
Operating activities | ||||||
Net income | -90.21M | -60.34M | -50.15M | -40.57M | -68.81M | -18.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 881K | 1.03M | 512K | 394K | 195K | 65K |
Stock-based compensation expense | 25.53M | 10.76M | 8.14M | 1.69M | 668K | 0 |
| Deferred income tax benefit | 25.53M | 10.76M | 8.14M | 1.69M | 668K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.14M | -722K | 1.72M | -1.14M | 722K | 488K |
Cash generated by operating activities | -67.39M | -49.10M | -41.82M | -29.80M | -66.22M | -18.07M |
Investing activities | ||||||
Purchases Of Investments | -275.78M | -139.73M | -166.29M | -715K | -58.38M | -6.94M |
Investments In Property Plant And Equipment | -52K | -275K | -340K | -584K | -900K | -244K |
Acquisitions Net | 0 | 21.99K | 119.35K | -7.27K | 2.95K | 0 |
Cash generated by investing activities | -37.98M | -22.27M | -119.69M | 6.69M | -3.85M | -4.77M |
Financing activities | ||||||
Common Stock Issued | 41.61M | 167.25M | 136.36M | 69.37M | 26K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -12.88M | -16.87M | 58K | 0 |
Cash used in financing activities | 41.95M | 167.49M | 134.39M | 85.51M | 62K | 99.76M |
Net Change In Cash | -63.30M | 95.53M | -27.15M | 62.47M | -70.14M | 77.01M |
Cash at end of period | 79.92M | 143.23M | 47.69M | 74.85M | 12.37M | 82.52M |
| Data source | Data source | Data source | Data source |